|
1
|
El-Salhy M, Gundersen D, Gilja OH,
Hatlebakk JG and Hausken T: Is irritable bowel syndrome an organic
disorder? World J Gastroenterol. 20:384–400. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
El-Salhy M, Gundersen D, Hatlebakk JG and
Hausken T: Irritable bowel syndrome. Nova Science; Publisher, New
York, NY: pp. 1–160. 2012
|
|
3
|
Simrén M, Månsson A, Langkilde AM,
Svedlund J, Abrahamsson H, Bengtsson U and Björnsson ES:
Food-related gastrointestinal symptoms in the irritable bowel
syndrome. Digestion. 63:108–115. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Monsbakken KW, Vandvik PO and Farup PG:
Perceived food intolerance in subjects with irritable bowel
syndrome - etiology, prevalence and consequences. Eur J Clin Nutr.
60:667–672. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Williams EA, Nai X and Corfe BM: Dietary
intakes in people with irritable bowel syndrome. BMC Gastroenterol.
11(9)2011. View Article : Google Scholar
|
|
6
|
Gibson PR, Barrett JS and Muir JG:
Functional bowel symptoms and diet. Intern Med J. 43:1067–1074.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gibson PR, Newnham E, Barrett JS, Shepherd
SJ and Muir JG: Review article: fructose malabsorption and the
bigger picture. Aliment Pharmacol Ther. 25:349–363. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gibson PR and Shepherd SJ: Evidence-based
dietary management of functional gastrointestinal symptoms: the
FODMAP approach. J Gastroenterol Hepatol. 25:252–258. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gunawardene AR, Corfe BM and Staton CA:
Classification and functions of enteroendocrine cells of the lower
gastrointestinal tract. Int J Exp Pathol. 92:219–231. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Rindi G, Leiter AB, Kopin AS, Bordi C and
Solcia E: The 'normal' endocrine cell of the gut: changing concepts
and new evidences. Ann N Y Acad Sci. 1014:1–12. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Polak JM, Coulling I, Bloom S and Pearse
AG: Immunofluorescent localization of secretin and enteroglucagon
in human intestinal mucosa. Scand J Gastroenterol. 6:739–744. 1971.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Taupenot L, Harper KL and O'Connor DT: The
chromogranin-secretogranin family. N Engl J Med. 348:1134–1149.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wiedenmann B and Huttner WB: Synaptophysin
and chromogranins/secretogranins - widespread constituents of
distinct types of neuroendocrine vesicles and new tools in tumor
diagnosis. Virchows Arch B Cell Pathol Incl Mol Pathol. 58:95–121.
1989. View Article : Google Scholar
|
|
14
|
Deftos LJ: Chromogranin A: its role in
endocrine function and as an endocrine and neuroendocrine tumor
marker. Endocr Rev. 12:181–187. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
El-Salhy M, Gilja OH, Gundersen D,
Hatlebakk JG and Hausken T: Duodenal chromogranin a cell density as
a biomarker for the diagnosis of irritable bowel syndrome.
Gastroenterol Res Pract. 2014:4628562014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
El-Salhy M, Gilja OH and Hausken T:
Chromogranin A cells in the stomachs of patients with sporadic
irritable bowel syndrome. Mol Med Rep. 10:1753–1757.
2014.PubMed/NCBI
|
|
17
|
El-Salhy M, Lomholt-Beck B and Hausken T:
Chromogranin A as a possible tool in the diagnosis of irritable
bowel syndrome. Scand J Gastroenterol. 45:1435–1439. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
El-Salhy M, Mazzawi T, Gundersen D and
Hausken T: Chromogranin A cell density in the rectum of patients
with irritable bowel syndrome. Mol Med Rep. 6:1223–1225.
2012.PubMed/NCBI
|
|
19
|
El-Salhy M, Wendelbo IH and Gundersen D:
Reduced chromogranin A cell density in the ileum of patients with
irritable bowel syndrome. Mol Med Rep. 7:1241–1244. 2013.PubMed/NCBI
|
|
20
|
Mazzawi T, Hausken T, Gundersen D and
El-Salhy M: Effects of dietary guidance on the symptoms, quality of
life and habitual dietary intake of patients with irritable bowel
syndrome. Mol Med Rep. 8:845–852. 2013.PubMed/NCBI
|
|
21
|
Mazzawi T, Hausken T, Gundersen D and
El-Salhy M: Effect of dietary management on the gastric endocrine
cells in patients with irritable bowel syndrome. Eur J Clin Nutr.
69:519–524. 2015. View Article : Google Scholar :
|
|
22
|
Mazzawi T, Gundersen D, Hausken T and
El-Salhy M: Increased gastric chromogranin A cell density following
changes to diets of patients with irritable bowel syndrome. Mol Med
Rep. 10:2322–2326. 2014.PubMed/NCBI
|
|
23
|
Mazzawi T, Gundersen D, Hausken T and
El-Salhy M: Increased chromogranin a cell density in the large
intestine of patients with irritable bowel syndrome after receiving
dietary guidance. Gastroenterol Res Pract. 2015:8238972015.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Mazzawi T, Hausken T, Gundersen D and
El-Salhy M: Dietary guidance normalizes large intestinal endocrine
cells densities in patients with irritable bowel syndrome. Eur J
Clin Nutr. 70:175–181. 2016. View Article : Google Scholar :
|
|
25
|
Masson LF, McNeill G, Tomany JO, Simpson
JA, Peace HS, Wei L, Grubb DA and Bolton-Smith C: Statistical
approaches for assessing the relative validity of a food-frequency
questionnaire: use of correlation coefficients and the kappa
statistic. Public Health Nutr. 6:313–321. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Brantsaeter AL, Haugen M, Alexander J and
Meltzer HM: Validity of a new food frequency questionnaire for
pregnant women in the Norwegian Mother and Child Cohort Study
(MoBa). Matern Child Nutr. 4:28–43. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
El-Salhy M, Stenling R and Grimelius L:
Peptidergic innervation and endocrine cells in the human liver.
Scand J Gastroenterol. 28:809–815. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Enck P, Klosterhalfen S and Kruis W:
Determination of placebo effect in irritable bowel syndrome.
Deutsche medizinische Wochenschrift (1946). 130:1934–1937. 2005.In
German. View Article : Google Scholar
|
|
29
|
Ostgaard H, Hausken T, Gundersen D and
El-Salhy M: Diet and effects of diet management on quality of life
and symptoms in patients with irritable bowel syndrome. Mol Med
Rep. 5:1382–1390. 2012.PubMed/NCBI
|
|
30
|
Abdul-Baki H, El Hajj II, Elzahabi L, Azar
C, Aoun E, Skoury A, Chaar H and Sharara AI: A randomized
controlled trial of imipramine in patients with irritable bowel
syndrome. World J Gastroenterol. 15:3636–3642. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zernicke KA, Campbell TS, Blustein PK,
Fung TS, Johnson JA, Bacon SL and Carlson LE: Mindfulness-based
stress reduction for the treatment of irritable bowel syndrome
symptoms: a randomized wait-list controlled trial. Int J Behav Med.
20:385–396. 2013. View Article : Google Scholar
|
|
32
|
Halmos EP, Power VA, Shepherd SJ, Gibson
PR and Muir JG: A diet low in FODMAPs reduces symptoms of irritable
bowel syndrome. Gastroenterology. 146:67–75.e5. 2014. View Article : Google Scholar
|
|
33
|
Khan WI and Ghia JE: Gut hormones:
Emerging role in immune activation and inflammation. Clin Exp
Immunol. 161:19–27. 2010.PubMed/NCBI
|
|
34
|
Helle KB: Regulatory peptides from
chromogranin A and secretogranin II: putative modulators of cells
and tissues involved in inflammatory conditions. Regul Pept.
165:45–51. 2010. View Article : Google Scholar
|
|
35
|
May CL and Kaestner KH: Gut endocrine cell
development. Mol Cell Endocrinol. 323:70–75. 2010. View Article : Google Scholar :
|
|
36
|
Sandström O and El-Salhy M: Ageing and
endocrine cells of human duodenum. Mech Ageing Dev. 108:39–48.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
El-Salhy M: Ghrelin in gastrointestinal
diseases and disorders: A possible role in the pathophysiology and
clinical implications (Review). Int J Mol Med. 24:727–732. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Tolhurst G, Reimann F and Gribble FM:
Intestinal sensing of nutrients. Handb Exp Pharmacol. 209:309–335.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Lee J, Cummings BP, Martin E, Sharp JW,
Graham JL, Stanhope KL, Havel PJ and Raybould HE: Glucose sensing
by gut endocrine cells and activation of the vagal afferent pathway
is impaired in a rodent model of type 2 diabetes mellitus. Am J
Physiol Regul Integr Comp Physiol. 302:R657–R666. 2012. View Article : Google Scholar
|
|
40
|
Parker HE, Reimann F and Gribble FM:
Molecular mechanisms underlying nutrient-stimulated incretin
secretion. Expert Rev Mol Med. 12:e12010. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Raybould HE: Nutrient sensing in the
gastrointestinal tract: Possible role for nutrient transporters. J
Physiol Biochem. 64:349–356. 2008. View Article : Google Scholar
|
|
42
|
San Gabriel A, Nakamura E, Uneyama H and
Torii K: Taste, visceral information and exocrine reflexes with
glutamate through umami receptors. J Med Invest. 56(Suppl):
209–217. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Rudholm T, Wallin B, Theodorsson E,
Näslund E and Hellström PM: Release of regulatory gut peptides
somatostatin, neurotensin and vasoactive intestinal peptide by acid
and hyperosmolal solutions in the intestine in conscious rats.
Regul Pept. 152:8–12. 2009. View Article : Google Scholar
|
|
44
|
Sternini C, Anselmi L and Rozengurt E:
Enteroendocrine cells: a site of 'taste' in gastrointestinal
chemosensing. Curr Opin Endocrinol Diabetes Obes. 15:73–78. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Sternini C: Taste receptors in the
gastrointestinal tract. IV. Functional implications of bitter taste
receptors in gastrointestinal chemosensing. Am J Physiol
Gastrointest Liver Physiol. 292:G457–G461. 2007. View Article : Google Scholar
|
|
46
|
Buchan AM: Nutrient tasting and signaling
mechanisms in the gut III. Endocrine cell recognition of luminal
nutrients. Am J Physiol. 277:G1103–G1107. 1999.PubMed/NCBI
|
|
47
|
Montero-Hadjadje M, Elias S, Chevalier L,
Benard M, Tanguy Y, Turquier V, Galas L, Yon L, Malagon MM,
Driouich A, et al: Chromogranin A promotes peptide hormone sorting
to mobile granules in constitutively and regulated secreting cells:
role of conserved N- and C-terminal peptides. J Biol Chem.
284:12420–12431. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Shooshtarizadeh P, Zhang D, Chich JF,
Gasnier C, Schneider F, Haïkel Y, Aunis D and Metz-Boutigue MH: The
antimicrobial peptides derived from chromogranin/secretogranin
family, new actors of innate immunity. Regul Pept. 165:102–110.
2010. View Article : Google Scholar
|
|
49
|
El-Salhy M, Hatlebakk JG, Gilja OH and
Hausken T: Irritable bowel syndrome: recent developments in
diagnosis, pathophysiology, and treatment. Expert Rev Gastroenterol
Hepatol. 8:435–443. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Höcker M and Wiedenmann B: Molecular
mechanisms of enteroendocrine differentiation. Ann N Y Acad Sci.
859:160–174. 1998. View Article : Google Scholar
|
|
51
|
Inokuchi H, Fujimoto S and Kawai K:
Cellular kinetics of gastrointestinal mucosa, with special
reference to gut endocrine cells. Arch Histol Jpn. 46:137–157.
1983. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
El-Salhy M, Hatlebakk JG and Hausken T:
Reduction in duodenal endocrine cells in irritable bowel syndrome
is associated with stem cell abnormalities. World J Gastroenterol.
21:9577–9587. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
El-Salhy M, Gilja OH, Gundersen D,
Hatlebakk JG and Hausken T: Interaction between ingested nutrients
and gut endocrine cells in patients with irritable bowel syndrome
(Review). Int J Mol Med. 34:363–371. 2014.PubMed/NCBI
|
